Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mucin degradation by Akkermansia muciniphila promotes Alistipes-dependent tryptophan metabolism and Th17-driven autoimmunity.

Mucosal immunology·2026
Same author

Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.

Brain : a journal of neurology·2026
Same author

Special Edition: Therapeutic advances in multiple sclerosis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author

Impact of sex on multiple sclerosis therapy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author

How Do I Approach the Evaluation and Treatment of Early Lyme Disease?

NEJM evidence·2024
Same author

SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.

Multiple sclerosis and related disorders·2024

Related Experiment Video

Updated: Jul 6, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Switching algorithms: from one immunomodulatory agent to another.

Patricia K Coyle1

  • 1Multiple Sclerosis Comprehensive Care Center, Stony Brook University Medical Center, Stony Brook, New York, USA. pcoyle@notes.cc.sunysb.edu

Journal of Neurology
|April 9, 2008
PubMed
Summary
This summary is machine-generated.

Switching disease-modifying therapies can be effective for multiple sclerosis patients unresponsive to initial treatments. This strategy offers a safe option when current therapies are inadequate or cause side effects.

More Related Videos

Induction and Assessment of Class Switch Recombination in Purified Murine B Cells
09:49

Induction and Assessment of Class Switch Recombination in Purified Murine B Cells

Published on: August 13, 2010

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: Jul 6, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Induction and Assessment of Class Switch Recombination in Purified Murine B Cells
09:49

Induction and Assessment of Class Switch Recombination in Purified Murine B Cells

Published on: August 13, 2010

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) has six disease-modifying treatments, yet some patients show inadequate response.
  • Factors like variable drug response, treatment timing, disease severity, and neutralizing antibodies necessitate therapy switches.

Purpose of the Study:

  • To evaluate the safety and efficacy of switching immunomodulatory therapies in multiple sclerosis patients.
  • To propose guidelines and an algorithm for making informed decisions about switching MS treatments.

Main Methods:

  • Review of observational studies, primarily focusing on switches from beta-interferons to glatiramer acetate.
  • Analysis of factors influencing treatment switching, including clinical and imaging criteria for treatment response.

Main Results:

  • Switching immunomodulatory therapy is demonstrated as safe and effective for MS patients with inadequate disease control.
  • Studies indicate successful outcomes when patients switch due to lack of efficacy or intolerable side effects.

Conclusions:

  • Therapy switching is a viable strategy for managing multiple sclerosis in non-responsive patients.
  • Proposed guidelines and algorithms can aid clinicians in deciding when to switch MS treatments.